Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

51Citations
Citations of this article
76Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In February 2018, the Melanoma Research Foundation and the Moffitt Cancer Center hosted the Second Summit on Melanoma Central Nervous System Metastases in Tampa, Florida. The meeting included investigators from multiple academic centers and disciplines. A consensus summary of the progress and challenges in melanoma parenchymal brain metastases was published (Eroglu et al., Pigment Cell & Melanoma Research, 2019, 32, 458). Here, we will describe the current state of basic, translational, clinical research, and therapeutic management, for melanoma patients with leptomeningeal disease. We also outline key challenges and barriers to be overcome to make progress in this deadly disease.

Cite

CITATION STYLE

APA

Glitza, I. C., Smalley, K. S. M., Brastianos, P. K., Davies, M. A., McCutcheon, I., Liu, J. K. C., … Forsyth, P. (2020, July 1). Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research. Blackwell Publishing Ltd. https://doi.org/10.1111/pcmr.12861

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free